Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression

Endo, Hitomi; Hama, Naoki; Baghdadi, Muhammad; Ishikawa, K.; Otsuka, Ryo; Wada, Haruka; Asano, Hiroshi; Endo, Daisuke; Konno, Yosuke; Kato, Tatsuya; Watari, Hidemichi; Tozawa, Akiko; Suzuki, Nao; Yokose, Tomoyuki; Takano, Atsushi; Kato, Hiroyuki; Miyagi, Yohei; Daigo, Yataro; Seino, Ken‐ichiro

doi:10.1093/intimm/dxz074

Cited by 26 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, further studies have found that IL-34 is highly expressed in ovarian cancer cells and tissues, which is associated with poor progression-free survival (PFS) and overall survival, while the expression of CSF-1 has not changed. Moreover, it's worth noting that compared with CSF-1, IL-34 has a stronger affinity for CSF1R (190). It can be seen that tumor cells may secrete high levels of IL-34 to stimulate the CSF1R signaling of TAMs to promote tumor progression.…”

Section: The Relationship Between Tumor Cells and Tams And Targeted Tmentioning

confidence: 99%

The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy

2020

View full text Add to dashboard Cite

Tumor microenvironment (TME) is composed of tumor cells and surrounding non-tumor stromal cells, mainly including tumor associated macrophages (TAMs), endothelial cells, and carcinoma-associated fibroblasts (CAFs). The TAMs are the major components of non-tumor stromal cells, and play an important role in promoting the occurrence and development of tumors. Macrophages originate from bone marrow hematopoietic stem cells and embryonic yolk sacs. There is close crosstalk between TAMs and tumor cells. With the occurrence of tumors, tumor cells secrete various chemokines to recruit monocytes to infiltrate tumor tissues and further promote their M2-type polarization. Importantly, M2-like TAMs can in turn accelerate tumor growth, promote tumor cell invasion and metastasis, and inhibit immune killing to promote tumor progression. Therefore, targeting TAMs in tumor tissues has become one of the principal strategies in current tumor immunotherapy. Current treatment strategies focus on reducing macrophage infiltration in tumor tissues and reprogramming TAMs to M1like to kill tumors. Although these treatments have had some success, their effects are still limited. This paper mainly summarized the recruitment and polarization of macrophages by tumors, the support of TAMs for the growth of tumors, and the research progress of TAMs targeting tumors, to provide new treatment strategies for tumor immunotherapy.

show abstract

Section: The Relationship Between Tumor Cells and Tams And Targeted Tmentioning

confidence: 99%

The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy

2020

View full text Add to dashboard Cite

show abstract

“…In lung cancers, IL-34 triggers activation of CCAAT/enhancer-binding protein β via AKT-mediated pathway with the downstream effect of enhancing the pro-tumorigenic and immunosuppressive functions of TAMs and consequently promoting the survival of chemoresistant cancer cells [36]. IL-34 is also expressed in human ovarian cancer cell lines and tissues [43]. IL-34 levels increase in ovarian cancer cell lines following treatment with cytotoxic agents and in the tumor tissues of chemotherapy-given ovarian cancer patients [43].…”

Section: Involvement Of Il-34 In Cancer Initiation and Progressionmentioning

confidence: 99%

“…IL-34 is also expressed in human ovarian cancer cell lines and tissues [43]. IL-34 levels increase in ovarian cancer cell lines following treatment with cytotoxic agents and in the tumor tissues of chemotherapy-given ovarian cancer patients [43]. Notably, high IL-34 expression correlates with worse progression-free survival and overall survival in different cohorts and in a mouse model of ovarian cancer [43].…”

Section: Involvement Of Il-34 In Cancer Initiation and Progressionmentioning

confidence: 99%

“…IL-34 levels increase in ovarian cancer cell lines following treatment with cytotoxic agents and in the tumor tissues of chemotherapy-given ovarian cancer patients [43]. Notably, high IL-34 expression correlates with worse progression-free survival and overall survival in different cohorts and in a mouse model of ovarian cancer [43]. Moreover, Han et al reported enhanced expression of IL-34 in a patient with metastatic melanoma who acquired resistance to anti-PD-1 immunotherapy (Nivolumab) [53].…”

Section: Involvement Of Il-34 In Cancer Initiation and Progressionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Interleukin-34 in Cancer

Franzè

Stolfi

Troncone

et al. 2020

Cancers

View full text Add to dashboard Cite

Cross-talk between cancer cells and the immune cells occurring in the tumor microenvironment is crucial in promoting signals that foster tumor growth and metastasis. Both cancer cells and immune cells secrete various interleukins (IL), which, either directly or indirectly, stimulate cancer-cell proliferation, survival, and diffusion, as well as contribute to sculpt the immune microenvironment, thereby amplifying tumorigenic stimuli. IL-34, a cytokine produced by a wide range of cells, has been initially involved in the control of differentiation, proliferation, and survival of myeloid cells. More recent studies documented the overexpression of IL-34 in several cancers, such as hepatocarcinoma, osteosarcoma, multiple myeloma, colon cancer, and lung cancer, and showed that tumor cells can produce and functionally respond to this cytokine. In this review, we summarize the multiple roles of IL-34 in various cancers, with the aim to better understand the relationship between the expression of this cytokine and cancer behavior and to provide new insights for exploring a new potential therapeutic target.

show abstract

“…Genes related to Treg infiltration also include the IL-related gene IL-1β, which induces Treg infiltration through the CCL22-CCR4-Foxp3 pathway and participates in the development of HNSCC (Li et al, 2019). Other IL-related genes can promote tumor metastasis (León et al, 2015;Sénécal et al, 2016;Goh and Hong, 2017;Endo et al, 2020). Growth factor-related genes are also associated with tumor metastasis, among which LTα, TNFRSF12α, TNFRSF25, TNFRSF4, and IRF9 can mediate HNSCC tumorigenesis and metastasis through the NF-κB signaling pathway (Schreiber et al, 2012;Lauenborg et al, 2015;Nan et al, 2018;Qiu et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Development of an Immunogenomic Landscape-Based Prognostic Index of Head and Neck Squamous Cell Carcinoma

Long

Zhang

Zeng

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the eighth leading cancer by incidence worldwide, with approximately 700,000 new cases in 2018 (accounting for 11% of all cancers). The occurrence and development of tumors are closely related to the immunological function of the body and sensitivity to treatment schemes as well as prognosis. It is urgent for clinicians to systematically study patients’ immune gene maps to help select a treatment plan and analyze the potential to cure HNSCC. Here, the transcriptomic data of HNSCC samples were downloaded from The Cancer Genome Atlas (TCGA), and 4,793 genes differentially expressed in normal and cancer tissues of HNSCC were identified, including 1,182 downregulated and 3,611 upregulated genes. From these genes, 400 differentially expressed immune-related genes (IRGs) were extracted, including 95 downregulated genes and 305 upregulated genes. The prognostic values of IRGs were evaluated by univariate Cox analysis, and 236 genes that were significantly related to the overall survival (OS) of patients were identified. The signaling pathways that play roles in the prognosis of IRGs were investigated by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, and the expression profiles of IRGs and OS in 499 HNSCC patients based on TCGA dataset were integrated. Potential molecular mechanisms and characteristics of these HNSCC-specific IRGs were further explored with the help of a new prognostic index based on IRGs developed by least absolute shrinkage and selection operator (LASSO) Cox analysis. A total of 64 hub genes (IRGs associated with prognosis) were markedly associated with the clinical outcome of HNSCC patients. KEGG functional enrichment analysis revealed that these genes were actively involved in several pathways, e.g., cytokine–cytokine receptor interaction, T-cell receptor signaling, and natural killer cell-mediated cytotoxicity. IRG-based prognostic signatures performed moderately in prognostic predictions. Interestingly, the prognostic index based on IRGs reflected infiltration by several types of immune cells. These data screened several IRGs of clinical significance and revealed drivers of the immune repertoire, demonstrating the importance of a personalized IRG-based immune signature in the recognition, surveillance, and prognosis of HNSCC.

show abstract

Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression

Cited by 26 publications

References 34 publications

The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy

The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy

Role of Interleukin-34 in Cancer

Development of an Immunogenomic Landscape-Based Prognostic Index of Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About